Geoffrey S.  Martha net worth and biography

Geoffrey Martha Biography and Net Worth

CEO of Medtronic
Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman and CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as one of healthcare’s most driven and innovative executives — ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.

The Medtronic Mission — to alleviate pain, restore health, and extend life — has inspired its researchers and engineers to create some of the most meaningful medical technologies in the history of healthcare: a pacemaker the size of a vitamin pill, the world’s first hybrid closed-loop diabetes pump, neurostimulators for pain and brain disorders, and more.

Under Geoff’s leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare, including manufacturing processes, robotics, data, machine learning, and artificial intelligence. Recognizing the power of partnerships and innovative collaborations, Geoff has accelerated Medtronic’s strategic acquisitions, boldly pursued novel R&D funding models, and embraced new ways to partner across industries and global borders.

Geoff assumed his current role as CEO in April 2020 — at the height of the COVID-19 pandemic. As part of his commitment to lead with purpose, Geoff quickly mobilized the company and took action to help global healthcare professionals and partners continue to treat patients and protect themselves. In addition to accelerating the development of remote solutions, he made the unprecedented move to open source the company’s intellectual property, making proprietary ventilator designs available to manufacturers around the world. The move helped address growing global demand for ventilators, resulted in new partnerships, and broke down barriers across industries to enhance care.

Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies. During Geoff’s tenure as CEO, Medtronic has also placed #11 on DiversityInc’s 2021 Top 50 Companies for Diversity; Drucker Institute’s 2020 Management Top 250 list; and the Dow Jones Sustainability North America Index, as one of the world's leading companies in sustainability.

Since joining Medtronic in 2011, Geoff has remained an ardent supporter of Medtronic-sponsored philanthropic and diversity initiatives. He is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics. Geoff also led the Medtronic African Descent Network ― an internal resource group focused on recruitment, engagement, retention, and development for employees of African descent.

Prior to becoming CEO of Medtronic, Geoff held various leadership roles on the company’s executive committee, including SVP, Strategy and Business Development; Chief Integration Officer; and Executive Vice President, Restorative Therapies Group. Notably, he led the acquisition and subsequent integration of Covidien, the largest acquisition in the history of the medical technology industry. Before joining Medtronic, Geoff spent 19 years in a variety of business development, strategic marketing, and sales management roles at GE Healthcare and GE Capital.

Geoff is an active member of the global business community, sitting on the Business Roundtable, and on the World Economic Forum’s International Business Council. He co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group. Passionate about socio-economic issues, Geoff also serves on the boards of two Minneapolis-based nonprofit organizations: Children’s HeartLink and Northside Achievement Zone (NAZ). He is also part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans.

Geoff received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University, graduating with highest honors. He was captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame. In 2016, the University awarded him the Penn State Hockey Distinguished Alumni Award. He is also a member of Penn State’s College of Liberal Arts Development Council.

What is Geoffrey S. Martha's net worth?

The estimated net worth of Geoffrey S. Martha is at least $8.48 million as of August 25th, 2021. Mr. Martha owns 97,317 shares of Medtronic stock worth more than $8,479,230 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Martha may own. Additionally, Mr. Martha receives a salary of $1,790,000.00 as CEO at Medtronic. Learn More about Geoffrey S. Martha's net worth.

How old is Geoffrey S. Martha?

Mr. Martha is currently 54 years old. There are 6 older executives and no younger executives at Medtronic. Learn More on Geoffrey S. Martha's age.

What is Geoffrey S. Martha's salary?

As the CEO of Medtronic plc, Mr. Martha earns $1,790,000.00 per year. Learn More on Geoffrey S. Martha's salary.

How do I contact Geoffrey S. Martha?

The corporate mailing address for Mr. Martha and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Geoffrey S. Martha's contact information.

Has Geoffrey S. Martha been buying or selling shares of Medtronic?

Geoffrey S. Martha has not been actively trading shares of Medtronic during the past quarter. Most recently, Geoffrey Martha sold 11,581 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $132.67, for a transaction totalling $1,536,451.27. Following the completion of the sale, the chief executive officer now directly owns 97,317 shares of the company's stock, valued at $12,911,046.39. Learn More on Geoffrey S. Martha's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 7 times. They sold a total of 55,558 shares worth more than $4,712,507.68. The most recent insider tranaction occured on February, 21st when EVP Sean Salmon sold 30,695 shares worth more than $2,613,065.35. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 2/21/2024.

Geoffrey S. Martha Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Sell11,581$132.67$1,536,451.2797,317View SEC Filing Icon  
6/28/2021Sell11,500$125.29$1,440,835.00View SEC Filing Icon  
6/6/2019Sell11,000$96.05$1,056,550.00View SEC Filing Icon  
9/24/2018Sell49,799$97.93$4,876,816.0787,872View SEC Filing Icon  
7/15/2016Sell3,766$88.26$332,387.16View SEC Filing Icon  
See Full Table

Geoffrey S. Martha Buying and Selling Activity at Medtronic

This chart shows Geoffrey Martha's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $87.13
Low: $86.93
High: $87.73

50 Day Range

MA: $85.23
Low: $83.08
High: $88.09

2 Week Range

Now: $87.13
Low: $68.84
High: $92.02

Volume

7,578,551 shs

Average Volume

6,322,563 shs

Market Capitalization

$115.69 billion

P/E Ratio

27.75

Dividend Yield

3.30%

Beta

0.76